Abstract
The benzodiazepines are typified by a profile of side effects which includes drowsiness, ataxia and incoordination. Ro 15-1788, an imidazodiazepine derivative, exhibits marked antagonism of the behavioural and biochemical effects of the benzodiazepines in animals and man. It is devoid of any behavioural activity in animals, except at very high doses. In the present study the effects of single rising oral doses of Ro 15-1788 on cognitive, psychomotor and subjective function in man have been assessed using a battery of psychometric tests designed to identify the sedative action of the benzodiazepines. At all doses up to 600 mg, Ro 15-1788 demonstrated none of the classical behavioural effects of the benzodiazepines.
This is a preview of subscription content, log in via an institution to check access.
References
Bond AS, Lader MH (1974) The use of visual analogue scales in rating subjective feelings. Br J Med Psychol 47:211–218
Bonetti EP, Pieri L, Cumin R, Schaffner R, Peri M, Gamzu ER, Muller RK, Haefely W (1982) Benzodiazepine antagonist Ro 15-1788: Neurological and behavioural effects. Psychopharmacology 78: 8–18
Costa E, Guidotti A (1979) Molecular mechanisms in the receptor action of benzodiazepines. Ann Rev Pharmacol 19:531–545
Costa E, Guidotti A (1982) Molecular mechanisms whereby benzodiazepines interact with gamma-aminobutyric acid recognition sites. In: Collu R, Ducharme JR, Barbeau A, Tolis G (eds) Brain neurotransmitters and hormones. Raven, New York, p 107
Dantzer R, Perio A (1982) Behavioural evidence for partial agonist properties of Ro 15-1788, a benzodiazepine receptor antagonist. Eur J Pharmacol 81:655–658
Darragh A, Lambe R, Scully M, Brick I, O'Boyle C, Downie WW (1981) Investigation in man of the efficacy of a benzodiazepine antagonist Ro 15-1788. Lancet ii:8–10
Darragh A, Lambe R, Kenny M, Brick I, Taaffe W, O'Boyle C (1982) Ro 15-1788 antagonizes the central effects of diazepam in man without altering diazepam bioavailability. Br J Clin Pharmacol 14:677–682
File SE, Bond AJ, Lister RC (1982) Interaction between effects of caffeine and lorazepam in performance tests and self-ratings. J Clin Psychopharmacol 2:102–106
Haefely W, Pieri L, Polc P, Schaffner R (1981) General pharmacology and neuropharmacology of benzodiazepine derivatives. In: Hoffmeister F, Stille G (eds) Handbook of experimental pharmacology, vol 55, Psychotropic agents, Part II. Springer, Berlin Heidelberg New York, p 13
Haefely W (1982) Behavioural and neuropharmacological aspects of benzodiazepines. In: Collu R, Ducharme JR, barbeau A, Tolis G (eds) Brain neurotransmitters and hormones. Raven, New York, p 81
Hindmarch I (1981) Psychomotor function and psychoactive drugs. In: Lader Richens A (eds) Methods in clinical pharmacology — central nervous system. Macmillan, London, p 29
Hunkeler W, Mohler H, Pieri I, Polc P, Bonetti EP, Cumin R, Schaffner R, Hacfely W (1981) Selective antagonists of benzodiazepines. Nature 290:514–516
Lloyd KG, Bovier P, Broekkamp CL, Worms P (1981) Reversal of the antiaversive and anticonvulsant actions of diazepam, but not progabide, by a selective antagonist of benzodiazepine receptors. Eur J Pharmacol 75:77–78
Mohler H, Okada T (1977) Benzodiazepine receptor: demonstration in the central nervous system. Science 198:849–851
Mohler H, Richards JG (1981) Agonist and antagonist benzodiazepine receptor interaction in vitro. Nature 294:763–765
Mohler H, Richards JG, Wu JY (1981a) Autoradiographic localization of benzodiazepine receptors in immunocytochemically identified-γ-aminobutyric synapses. Proc Natl Acad Sci USA 78:1935–1938
Mohler H, Burkard WP, Keller HH, Richard JG, Haefely W (1981b) Benzodiazepine antagonist Ro 15-1788: Binding characteristics and interactions with drug-induced changes in dopamine turnover and cerebellar cGMP levels. J Neurochem 37:714–722
Nutt DJ, Cowen PJ, Little HJ (1982) Unusual interactions of benzodiazepine receptor antagonist. Nature 295:436–438
O'Boyle C, Lambe R, Darragh A, Taaffe W, Brick I, Kenny M (1983) Ro 15-1788 antagonizes the amnesic effects of diazepam in man without affecting diazepam bioavailability. Br J Anaesth, in press
Polc P, Laurent JP, Scherschlicht R, Haefely W (1981) Electrophysiological studies on the specific benzodiazepine antagonist Ro 15-1788. Naunyn-Schmiedeberg's Arch Pharmacol 316:317–325
Smith JM, Misiak H (1976) Critical flicker frequency (CFF) and psychotropic drugs in normal human subjects — A review. Psychopharmacology 47:175–182
Squires RF, Braestrup C (1977) Benzodiazepine receptors in rat brain. Nature 266:732–734
Tallman JF, Paul SM, Skolnick P, Gallagher DW (1980) Receptors for the age of anxiety: Pharmacology of the benzodiazepines. Science 207:274–281
Teichner WH, Krebs MJ (1972) Laws of simple visual reaction time. Psychol Rev 79:344–345
Thurstone LL (1966) Perceptual speed test administration manual (revised). Industrial relations centre: University of Chicago
Turner P (1981) Tests of automatic function in assessing centrally acting drugs. In: Lader M, Richens A (eds) Methods in clinical pharmacology —central nervous system. Macmillan, London, p 21
Tyer P (1976) The role of bodily feelings in anxiety. Institute of Psychiatry — Maudsley Monographs, No. 23, Oxford University Press
Vogel JR (1979) Objective measurement of human performance changes produced by anxiolytic drugs. In: Fielding J, Lal S (eds) Anxiolytics. Futura, New York, p 343
Wechsler D (1955) A manual for the Wechsler Adult Intelligence Scale. Psychological Corporation, New York
Wittenborn JR (1978) Behavioural toxicity in normal humans as a model for assessing behavioural toxicity in patients. In: Lipton MA, DiMascio A, Killam KF (eds) Psychopharmacology, a generation of progress, Raven, New York, p 791
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Darragh, A., Lambe, R., O'Boyle, C. et al. Absence of central effects in man of the benzodiazepine antagonist Ro 15-1788. Psychopharmacology 80, 192–195 (1983). https://doi.org/10.1007/BF00427969
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00427969